Angle PLC Leading cancer surgeon appointed
May 14 2018 - 2:00AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
14 May 2018
For immediate release 14 May 2018
ANGLE plc ("the Company")
LEADING NHS PROSTATE CANCER SURGEON APPOINTED AS SCIENTIFIC
ADVISOR
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce the appointment of Mr Greg L Shaw
as a Scientific Advisor to the Company.
Joining the Company's already established Scientific Advisory
Board, Mr Shaw brings significant additional prostate cancer and UK
NHS clinical experience.
Mr Shaw is a Consultant Urological Surgeon at University College
Hospital in London and is a clinical academic with a strong
interest in prostate cancer diagnostics and treatment. Having
completed an M.D. in prostate cancer at the University of London
investigating circulating tumour cells in prostate cancer, and
subsequently completed four years as a lecturer at the University
of Cambridge, Mr Shaw has published widely on prostate cancer and
is currently an honorary senior lecturer at University College and
Queen Mary College of the University of London.
He leads several research programs focused on current weaknesses
in the way prostate cancer is treated and is interested in
exploring the role novel biomarkers may play in advancing practice
in these areas.
Mr Shaw is currently chief investigator for two NIHR portfolio
studies investigating 1) the effects of refinements to robotic
surgery and 2) the use of drugs to prevent progression in men on
active surveillance for prostate cancer respectively.
Mr Shaw is an expert in robotic surgery with a high case volume.
He is known for his innovative approach and commitment to quality
assurance.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"As we prepare to extend our prostate cancer work, we are
delighted that we will be able to benefit from Greg Shaw's
extensive experience in this area. Greg's understanding of current
clinical practice in the UK and the key areas of medical need that
liquid biopsy can address will help us to position Parsortix(TM)
clinical applications for prostate cancer in the future."
Mr Greg Shaw, Consultant Urological Surgeon at University
College Hospital, said:
"I am delighted to be joining ANGLE's Scientific Advisory Board.
Having worked as a Consultant Urological Surgeon pursuing a
specialist interest in prostate cancer over the last 14 years, I am
encouraged by the development of the Parsortix system and the
potential it holds for the diagnosis and assessment of prostate
cancer. I look forward to helping the ANGLE team as they progress
the development of prostate cancer clinical applications, using the
Parsortix system."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Adrian Hargrave,
Simon Hicks, Kate Bannatyne
Corporate Broking - Alice Lane, Nikita
Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000
Evan Smith, Anne Troy (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called Ziplex(R) and is based on a patented flow
through array technology. It provides for highly multiplexed, rapid
and sensitive capture of targets from a wide variety of sample
types. A proprietary chemistry allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. These technologies can be combined to provide fully
automated, sample to answer results in both centralised laboratory
and point of use cartridge formats. It is ideal for measuring gene
expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUORNRWOAVAAR
(END) Dow Jones Newswires
May 14, 2018 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024